Antitoxin Levels in Botulism Patients Treated with Trivalent Equine Botulism Antitoxin to Toxin Types A, B, and E
- 1 September 1984
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 150 (3), 407-412
- https://doi.org/10.1093/infdis/150.3.407
Abstract
Serum levels of equine-botulism antitoxin to toxin types A, B, and E were measured in four. type-A botulism patients who had received equine-botulism antitoxin. High circulating levels capable of neutralizing in excess of 1 × 108, 9 × 107, and 6 × 106 50% mouse lethal doses of toxin of types A, B, and E, respectively, were detected. There was little depletion of type-A antitoxin even though two of the patients had circulating type-A toxin before treatment. The half-life for antitoxin persistence for one patient was calculated as being 6.5, 7.6, and 5.3 days for antitoxin types A, B, and E, respectively. Antitoxin levels were not proportionate to the amount (range, 2–4 vials) injected and did not appear to be affected by whether the route of administration was iv or im. Peak serum levels of antitoxin were 10–1,000 times higher than amounts needed to neutralize the toxin measured in the serum of these and other patients with botulism.Keywords
This publication has 4 references indexed in Scilit:
- RESTAURANT-ASSOCIATED TYPE A BOTULISM: TRANSMISSION BY POTATO SALADAmerican Journal of Epidemiology, 1981
- Hypersensitivity reactions associated with botulinal antitoxinAmerican Journal Of Medicine, 1980
- HUMAN BOTULISM CAUSED BY CLOSTRIDIUM-BOTULINUM TYPE-E - BIRMINGHAM OUTBREAK1979
- Coproexamination for botulinal toxin and clostridium botulinum. A new procedure for laboratory diagnosis of botulismJAMA, 1977